. . . "In the past decade the management strategies of patients with chronic myeloid leukemia have been completely changes, imatinib became the standard front-line therapy in patients with newly diagnosed chronic-phase CML. Allogeneic stem cell transplantation in CML patients is increasingly deferred despite its curative potential. Second generation tyrosine kinase inhibitors dasatinib and nilotinib together with the improved molecular monitoring or residual leukemia and the identification of BCR-ABL1 mutations with wide spectrum of sensitivity to tyrosine kinase inhibitors make possible the tailoring of CML treatment. Current recommendations for the management of CML are reviewed."@en . "stem cell transplantation; tyrosine kinase inhibitors; therapy; chronic myeloid leukemia"@en . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leukemie u dosp\u011Bl\u00FDch v roce 2010" . . "Voglov\u00E1, Jaroslava" . "7"^^ . "RIV/00179906:_____/10:10061866!RIV11-MZ0-00179906" . "4" . "1"^^ . "268111" . . "Treatment of chronic myeloid leukemia in adults in 2010"@en . "Onkologie" . "Treatment of chronic myeloid leukemia in adults in 2010"@en . . "V" . . . "1"^^ . "1802-4475" . "CZ - \u010Cesk\u00E1 republika" . . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leukemie u dosp\u011Bl\u00FDch v roce 2010"@cs . "[61A0D26DB902]" . . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leukemie (CML) se b\u011Bhem posledn\u00EDho desetilet\u00ED z\u00E1sadn\u011B zm\u011Bnila. Imatinib se stal standardn\u00EDm l\u00E9kem prvn\u00ED volby pro nemocn\u00E9 v chronick\u00E9 f\u00E1zi CML. D\u0159\u00EDve preferovan\u00E1 alogenn\u00ED transplantace krvetvorn\u00FDch bun\u011Bk se odkl\u00E1d\u00E1 do dal\u0161\u00EDch lini\u00ED l\u00E9\u010Dby, p\u0159esto\u017Ee je to zat\u00EDm jedin\u00E1 potenci\u00E1ln\u011B kurativn\u00ED metoda pro CML. Inhibitory tyrozinkin\u00E1z 2. generace dasatinib a nilotinib, rozvoj molekul\u00E1rn\u00EDho monitorov\u00E1n\u00ED rezidu\u00E1ln\u00ED leukemie a identifikace \u0159ady mutac\u00ED BCR-ABL1 s r\u016Fznou senzitivitou k inhibitor\u016Fm tyrozinkin\u00E1z umo\u017E\u0148uj\u00ED l\u00E9\u010Dbu %22\u0161\u00EDt na m\u00EDru%22. V \u010Dl\u00E1nku je uveden p\u0159ehled sou\u010Dasn\u00FDch doporu\u010Den\u00ED pro l\u00E9\u010Dbu CML."@cs . . . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leukemie u dosp\u011Bl\u00FDch v roce 2010"@cs . . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leukemie (CML) se b\u011Bhem posledn\u00EDho desetilet\u00ED z\u00E1sadn\u011B zm\u011Bnila. Imatinib se stal standardn\u00EDm l\u00E9kem prvn\u00ED volby pro nemocn\u00E9 v chronick\u00E9 f\u00E1zi CML. D\u0159\u00EDve preferovan\u00E1 alogenn\u00ED transplantace krvetvorn\u00FDch bun\u011Bk se odkl\u00E1d\u00E1 do dal\u0161\u00EDch lini\u00ED l\u00E9\u010Dby, p\u0159esto\u017Ee je to zat\u00EDm jedin\u00E1 potenci\u00E1ln\u011B kurativn\u00ED metoda pro CML. Inhibitory tyrozinkin\u00E1z 2. generace dasatinib a nilotinib, rozvoj molekul\u00E1rn\u00EDho monitorov\u00E1n\u00ED rezidu\u00E1ln\u00ED leukemie a identifikace \u0159ady mutac\u00ED BCR-ABL1 s r\u016Fznou senzitivitou k inhibitor\u016Fm tyrozinkin\u00E1z umo\u017E\u0148uj\u00ED l\u00E9\u010Dbu %22\u0161\u00EDt na m\u00EDru%22. V \u010Dl\u00E1nku je uveden p\u0159ehled sou\u010Dasn\u00FDch doporu\u010Den\u00ED pro l\u00E9\u010Dbu CML." . . . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leukemie u dosp\u011Bl\u00FDch v roce 2010" . "RIV/00179906:_____/10:10061866" . "3" .